ECSP10010060A - Derivados de pirazol sustituídos - Google Patents

Derivados de pirazol sustituídos

Info

Publication number
ECSP10010060A
ECSP10010060A EC2010010060A ECSP10010060A ECSP10010060A EC SP10010060 A ECSP10010060 A EC SP10010060A EC 2010010060 A EC2010010060 A EC 2010010060A EC SP10010060 A ECSP10010060 A EC SP10010060A EC SP10010060 A ECSP10010060 A EC SP10010060A
Authority
EC
Ecuador
Prior art keywords
atom
group
group linked
linked
substituted
Prior art date
Application number
EC2010010060A
Other languages
English (en)
Inventor
Mitsuhiro Ito
Tomohiko Suzaki
Satoshi Yamamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP10010060A publication Critical patent/ECSP10010060A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

RESUMENSe describe un nuevo derivado de pirazol y un antagonista del receptor de andrógeno que contiene el derivado de pirazol. Se describe específicamente un compuesto representado por la fórmula (I') siguiente o una sal de él. (En la fórmula, R1 representa un átomo de hidrógeno, un grupo unido a través de un átomo de carbono, un grupo unido a través de un átomo de nitrógeno, un grupo unido a través de un átomo de oxígeno, o un grupo unido a través de un átomo de azufre; R2 representa un grupo fenilo que tiene un ciano (el cual puede tener además un sustituyente diferente de ciano); R3 es un átomo de hidrógeno, un grupo unido a través de un átomo de carbono, un grupo unido a través de un átomo de nitrógeno, un grupo unido a través de un átomo de oxígeno, o un grupo unido a través de un átomo de azufre; R4 representa un grupo cíclico sustituido opcionalmente; y X representa un metileno sustituido opcionalmente o CO).
EC2010010060A 2007-08-30 2010-03-30 Derivados de pirazol sustituídos ECSP10010060A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007224910 2007-08-30

Publications (1)

Publication Number Publication Date
ECSP10010060A true ECSP10010060A (es) 2010-04-30

Family

ID=40387261

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010060A ECSP10010060A (es) 2007-08-30 2010-03-30 Derivados de pirazol sustituídos

Country Status (20)

Country Link
US (2) US20100227846A1 (es)
EP (1) EP2194045A4 (es)
JP (1) JPWO2009028543A1 (es)
KR (1) KR20100046275A (es)
CN (1) CN101842357A (es)
AR (1) AR068813A1 (es)
AU (1) AU2008292429A1 (es)
BR (1) BRPI0816095A2 (es)
CA (1) CA2697663A1 (es)
CL (1) CL2008002521A1 (es)
CO (1) CO6190530A2 (es)
DO (1) DOP2010000068A (es)
EA (1) EA201070323A1 (es)
EC (1) ECSP10010060A (es)
MA (1) MA31714B1 (es)
MX (1) MX2010002266A (es)
PE (1) PE20090610A1 (es)
TN (1) TN2010000091A1 (es)
TW (1) TW200913993A (es)
WO (1) WO2009028543A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009123316A1 (ja) * 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
JP2013504531A (ja) * 2009-09-11 2013-02-07 バイエル・ファルマ・アクチェンゲゼルシャフト 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9000154B2 (en) 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
PH12013500534A1 (en) 2010-10-22 2017-08-09 Astellas Pharma Inc Antagonist for mutant androgen receptor
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
KR101958177B1 (ko) * 2011-04-21 2019-03-15 오리온 코포레이션 안드로겐 수용체 조절성 카복스아미드
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
JP6057698B2 (ja) * 2012-12-25 2017-01-11 東レ・ダウコーニング株式会社 イミド基含有有機ケイ素化合物の製造方法
US9981950B2 (en) 2014-08-15 2018-05-29 Janssen Pharmaceuticals, Inc. Triazoles as NR2B receptor inhibitors
WO2016025918A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Pyrazoles
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
BR112018000468A2 (pt) 2015-07-09 2018-09-18 Janssen Pharmaceutica Nv 4-azaindóis substituídos e seu uso como moduladores do receptor de glun2b
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
MA44008A (fr) 2016-02-10 2018-12-19 Janssen Pharmaceutica Nv 1,2,3-triazoles substitués utilisés comme modulateurs de nmda sélectifs de nr2b
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
MX393924B (es) * 2016-06-10 2025-03-24 Univ Tennessee Res Found Ligandos degradadores selectivos del receptor de andrógenos (sard) y métodos de uso de los mismos.
US10806719B2 (en) 2016-06-10 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
WO2018195155A1 (en) * 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Therapeutic compounds
CN107903213A (zh) * 2017-09-28 2018-04-13 山东大学 5‑甲基‑1h‑吡唑衍生物及其制备方法和应用
EP3774732A4 (en) 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
CN108676001A (zh) * 2018-06-12 2018-10-19 江西师范大学 一种3-取代-5-异噁唑基-4-取代-1-1,2,3-三氮唑基甲烷化合物
WO2020051344A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
EP3982958A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted heteroaromatic pyrazolo-pyridines and their use as glun2b receptor modulators
JP2022536773A (ja) 2019-06-14 2022-08-18 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
MX2021015511A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Carbamatos de pirazina y sus usos como moduladores del receptor glun2b.
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
CN113993583A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途
CR20210580A (es) 2019-06-14 2022-01-31 Janssen Pharmaceutica Nv Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
JP7288665B2 (ja) * 2019-08-02 2023-06-08 株式会社デ・ウエスタン・セラピテクス研究所 エチルアニリノトルエンスルホン酸誘導体の製造方法
CN111499539B (zh) * 2020-04-20 2022-10-11 南昌大学 一种以芳基羧酸为原料的芳基氰化物合成方法
MX2023001448A (es) * 2020-08-04 2023-06-22 Prec Bio Therapeutics S R L Compuestos de quinolina como moduladores selectivos y/o duales de los receptores del acido biliar y los receptores del cisteinil-leucotrieno.
AU2023307594A1 (en) * 2022-07-15 2024-11-28 Chong Kun Dang Pharmaceutical Corp. 1,3,4-oxadiazole triazole compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US401275A (en) * 1889-04-09 Wagon-tire
WO1998056785A1 (en) * 1997-06-12 1998-12-17 Sumitomo Pharmaceuticals Co., Ltd. Pyrazole derivatives
US20040229900A1 (en) * 1999-06-16 2004-11-18 Astrazeneca Ab Bispidine compounds useful in the treatment of cardiac arrythmias
SE0002603D0 (sv) * 2000-07-07 2000-07-07 Astrazeneca Ab New compounds
JP4310109B2 (ja) * 2001-04-26 2009-08-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
DE60226756D1 (de) * 2001-10-04 2008-07-03 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
ES2295441T3 (es) * 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
EP1458708B1 (en) * 2001-12-18 2007-09-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1458385A4 (en) * 2001-12-19 2005-12-21 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
EP1458710A4 (en) * 2001-12-21 2005-04-20 Merck & Co Inc Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) * 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
WO2003057669A1 (fr) * 2001-12-28 2003-07-17 Takeda Chemical Industries, Ltd. Antagonistes du recepteur androgene
CA2482382A1 (en) * 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
US20040127519A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040127511A1 (en) * 2002-12-12 2004-07-01 Pharmacia Corporation Tricyclic aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
US20040142978A1 (en) * 2002-12-12 2004-07-22 Pharmacia Corporation Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
US7880001B2 (en) * 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
WO2005111003A1 (en) * 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
TW200628446A (en) * 2004-12-14 2006-08-16 Takeda Pharmaceuticals Co Substituted pyrrole derivative
EP2016078B1 (en) * 2006-04-04 2016-06-15 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as hif modulators
JP2007332053A (ja) * 2006-06-13 2007-12-27 Takeda Chem Ind Ltd 置換ピロール誘導体
BRPI0811065A2 (pt) * 2007-06-08 2014-12-02 Abbott Lab Indazóis 5-heteroaril substituídos como inibidores de quinase
PE20091653A1 (es) * 2008-03-26 2009-11-14 Takeda Pharmaceutical Derivados sustituidos de pirazol y su uso

Also Published As

Publication number Publication date
CN101842357A (zh) 2010-09-22
AU2008292429A1 (en) 2009-03-05
WO2009028543A1 (ja) 2009-03-05
EP2194045A1 (en) 2010-06-09
EP2194045A4 (en) 2011-09-21
TN2010000091A1 (en) 2011-09-26
US20090270359A1 (en) 2009-10-29
KR20100046275A (ko) 2010-05-06
DOP2010000068A (es) 2010-03-15
CL2008002521A1 (es) 2009-11-20
PE20090610A1 (es) 2009-06-11
BRPI0816095A2 (pt) 2015-03-03
AR068813A1 (es) 2009-12-09
TW200913993A (en) 2009-04-01
MX2010002266A (es) 2010-03-25
JPWO2009028543A1 (ja) 2010-12-02
US20100227846A1 (en) 2010-09-09
CA2697663A1 (en) 2009-03-05
CO6190530A2 (es) 2010-08-19
MA31714B1 (fr) 2010-09-01
EA201070323A1 (ru) 2010-10-29

Similar Documents

Publication Publication Date Title
DOP2010000068A (es) Derivados de pirazol sustituidos
CO5690607A2 (es) Compuestos de piridina como inhibidores de dipeptidil peptidasa iv
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
PA8797301A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
AR063028A1 (es) Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
PT2380874T (pt) Compostos orgânicos
UA105185C2 (uk) Піроли
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
CR9421A (es) Compuestos heterociclicos fusionados
ECSP088113A (es) Nuevos derivados de pirazina
JO2864B1 (en) Circular amine compounds
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
CR11245A (es) Mejoras en compuestos organicos o relacionadas con los mismos
DOP2010000226A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos
MX2009012380A (es) Compuestos de heteroarilamida pirimidona.
CO6321168A2 (es) Nuevos derivados de 2-amidotiadiazol
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
MX2010008360A (es) Derivados de oxazepinopirimidona heteroarilamida sustituidos.
MX2019007684A (es) Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.
WO2008149834A1 (ja) ピリミドジアゼピノン誘導体
CO5700747A2 (es) Piperidinas novedosas como moduladores de quimoquina (ccr)
ES2422603T3 (es) Compuestos oxiimino y el uso de estos
CO6220956A2 (es) Derivados de pirazolona como inhibidores de pde4